CD8A and neoplasm: Due to the potent ability to promote CD8+ T cell expansion and cytotoxic activity, engineered IL-2 with increased affinity for CD122 (IL-2Rβ) have been demonstrated effective tumor control capability and response to immune checkpoint blockade.59,60,62,70 Those findings intrigued us to explore the potential cancer therapeutics of targeting ADAM17 in CD8+ T cells.